Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Hormone Research in Paediatrics, 70 (1), 5157
Its triple GIP/GLP-1/glucagon agonist mechanism produced the most striking weight-loss numbers ever reported in a Phase 2 trial of an injectable peptide, and its broad TRIUMPH Phase 3 program is poised to expand understanding of how triple receptor modulation affects obesity, diabetes, liver disease, cardiovascular risk, sleep apnea, and musculoskeletal health
Key mechanistic observations from laboratory studies: VEGF upregulation: BPC-157 is thought to upregulate VEGF expression
Most telehealth GLP-1 programs require a BMI of 27 or higher with a weight-related health condition, or a BMI of 30 or higher without comorbidities, consistent with FDA labeling for chronic weight management
People with prediabetes who have higher than usual but not yet diabetic blood sugar levels can technically qualify for a GLP-1 prescription under current FDA guidelines, but getting insurance to cover it is another matter
US$ 29.85
US$ 24.75
US$ 25.92
US$ 26.54
US$ 24.29
US$ 24.72
US$ 20.32
